Covishield; Not everyone who received the shot is at risk.

AstraZeneca, the developer and manufacturer of Covishield, has acknowledged that the vaccine may lead to a rare occurrence of thrombosis with thrombocytopenia syndrome (TTS) as a side effect.  The risk of TTS is, however, considered very rare. Not everyone who has received the Covishield is at risk. The side effects iof the vaccine will will be experienced in rarest of the rare cases. Nearly 88% of all vaccine doses administered in India have been Covishield shots. Over 75% of India’s adult population is now fully vaccinated against COVID-19. Covishield, from the Oxford/AstraZeneca stable, comprises over 90% of the 12.76 crore Covid-19 vaccines administered across the country so far. The probability of experiencing the risks associated with the Covishield vaccine is claimed to be minimal. The Indian government has been closely monitoring vaccine safety and efficacy to ensure public health during the pandemic.